SCYNEXIS
Update in progressSCYX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
SCYNEXIS, Inc. is a biotechnology company focused on developing medicines for difficult-to-treat and drug-resistant fungal infections in the United States. Its product BREXAFEMME is used to treat vulvovaginal candidiasis and to reduce repeat infections. The company is also developing SCY-247, currently in Phase I for invasive fungal infections. It was incorporated in 1999, renamed in 2002, and is based in Jersey City, New Jersey.
Company score
- Sentiment
- 0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.13
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. David Gonzalez Angulo M.D.
- Founded1999
- Employees18
- Websitewww.scynexis.com
Identifiers
- ISINUS8112922005
- FIGIBBG002133YW4
- CUSIP811292101
- CIK0001178253